Literature DB >> 9012550

Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury.

B A Wroblewski1, A B Joseph, J Kupfer, K Kalliel.   

Abstract

Valproic acid, a primary anticonvulsant drug, has recently been studied for purported effectiveness in disparate disorders of mood and behaviour. The psychopharmacological treatment of patients with acquired brain injury frequently includes numerous trials of psychotherapeutic drugs such as antipsychotics, benzodiazepines, antidepressants, and lithium, in an effort towards affective and behavioural improvement. In this report we describe and graphically depict the striking efficacy of valproic acid in reducing and improving destructive and aggressive behaviours in five patients with acquired brain injury. In all cases valproic acid was effective after other pharmacological interventions were not. Also, the addition of valproic acid was followed by neurobehavioural improvement rather quickly, often within 1-2 weeks. Advantages of valproic acid, in addition to its possible unique efficacy, include a lower propensity towards sedation and cognitive impairment, and thus a more robust potential for rehabilitation participation. Behaviours associated with affective disorders ranging along the affective spectrum from depression to dysphoric mania may be particularly amenable to valproic acid. The drug may also be beneficial in some cases in which another psychotropic anticonvulsant, carbamazepine, was not.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012550     DOI: 10.1080/026990597123791

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  12 in total

1.  Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.

Authors:  Indranil Bhattacharya; Kathleen M K Boje
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-08-29       Impact factor: 2.745

Review 2.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 4.  Common psychiatric syndromes and pharmacologic treatments of traumatic brain injury.

Authors:  L A Labbate; D L Warden
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

Review 5.  Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.

Authors:  Carlo Ignazio Cattaneo; Francesca Ressico; Roberta Valsesia; Pierluigi D'Innella; Matteo Ballabio; Michele Fornaro
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

Review 6.  The use of newer anticonvulsants in neuropsychiatric disorders.

Authors:  Edward Kim
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

7.  The neurobiological bases for development of pharmacological treatments of aggressive disorders.

Authors:  Allan Siegel; Suresh Bhatt; Rekha Bhatt; Steven S Zalcman
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

8.  Neuropsychiatric Aspects of Traumatic Brain Injury.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-03       Impact factor: 3.972

9.  Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.

Authors:  Andrew B Newberg; Mijail Serruya; Andrew Gepty; Charles Intenzo; Todd Lewis; Daniel Amen; David S Russell; Nancy Wintering
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

10.  Carglumic Acid Treatment of a Patient with Recurrent Valproic Acid-induced Hyperammonemia: A Rare Case Report.

Authors:  Yasar Sattar; Saad Wasiq; Waqas Yasin; Ali M Khan; Mahwish Adnan; Shristi Shrestha; Nirav B Patel; Sharaad Latchana
Journal:  Cureus       Date:  2018-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.